Setback for XLRP Community: J&J Gene Therapy Bota-vec Misses Primary Goal in Phase 3 Trial

Setback for XLRP Community: J&J Gene Therapy Bota-vec Misses Primary Goal in Phase 3 Trial

The inherited retinal disease (IRD) community is closely watching developments in gene therapy, a promising area of research for conditions like X-linked retinitis pigmentosa (XLRP). Recent news from Johnson & Johnson (J&J) regarding their experimental gene therapy, botaretigene sparoparvovec (bota-vec), for XLRP has brought a significant setback, as the treatment did not meet its primary endpoint in a late-stage clinical trial. This news, initially reported by The Pharma Letter in May 2025, underscores the complex journey of bringing new treatments to patients and highlights the ongoing need for research and development in this field.

Bota-vec, developed by J&J and MeiraGTx, is designed to deliver a functional version of the RPGR gene to rod and cone photoreceptors in the retina. XLRP is a severe form of retinitis pigmentosa, primarily affecting males, and is characterized by progressive vision loss that can lead to legal blindness, often by age 40.

Key Trial Findings

The Phase 3 LUMEOS trial, which enrolled 95 participants with XLRP caused by RPGR gene variants, evaluated bota-vec's effectiveness. The trial's primary endpoint was a vision-guided mobility assessment (VMA) at 52 weeks. J&J announced that bota-vec did not show a statistically significant improvement on this primary endpoint.

Despite missing the primary goal, J&J noted that the outcome was "directionally supportive" and that bota-vec showed improvements across several secondary measures. These included retinal function, functional vision, and visual function, with treatment differences observed in patient-reported outcomes, static perimetry, retinal sensitivity, and low luminance visual acuity. Approximately 40% of treated patients demonstrated improvement in at least two endpoints, compared to none in the deferred treatment arm.

Regarding safety, all treated participants experienced at least one treatment-emergent adverse event, with the majority (86%) being mild or moderate. Ocular inflammation occurred in about 70% of participants, and adverse events related to cataracts were reported in 29 treated participants versus six in the control group.

What This Means for Patients and Families

This news can be disheartening for individuals and families affected by XLRP who have been hopeful for new treatment options. While the primary endpoint was not met, the improvements seen in secondary endpoints suggest that the therapy may still hold some potential, and further analysis is underway. J&J is currently evaluating strategic options and next steps for bota-vec.

It's important to remember that the path to developing new therapies is often long and challenging, with many trials facing hurdles. This outcome highlights the complexity of inherited retinal diseases and the high bar for demonstrating statistically significant clinical benefit. The IRD community remains resilient, and research continues globally to find effective treatments for XLRP and other inherited retinal conditions. Other gene therapy programs for XLRP are still in development, offering continued hope for the future.

Looking Ahead

As of early July 2025, J&J has not announced a clear development plan or regulatory steps for bota-vec. The company is working to understand the totality of the data, including the clinical relevance of improvements in secondary endpoints. The IRD community will await further updates from J&J regarding the future of bota-vec and its potential role in the treatment landscape for XLRP.